The latest update is out from enVVeno Medical (NVNO).
enVVeno Medical Corporation revealed promising topline results from the SAVVE U.S. pivotal trial of their VenoValve® product at a recent symposium in London, suggesting significant clinical improvements. While these forward-looking statements offer optimism, they come with the usual caveats of potential risks and uncertainties inherent in clinical trials and the medical industry. The company reminds stakeholders that outcomes may differ from expectations and emphasizes its commitment to transparency in accordance with legal requirements.
Find detailed analytics on NVNO stock on TipRanks’ Stock Analysis page.
